Molecular Templates Inc (MTEM)

[The_BORG]

So what’s next? Well, the likely major near-term catalyst will come from the registration process in Japan. The company is seeking approval of the failed and above mentioned oncology target, and as this progresses, we will likely see markets move on the inference of its progression points. It’s a long shot, however, and there’s every chance that Japanese regulators will request some sort of extension trial to reinforce what is essentially an anomalous result from the phase 3 on which the application rests.

Beyond that, we will be watching the Evofosfamide phase 1s closely to see if the drug can show any sort of clinical benefit, or whether it is likely to just burn out as it has done in the past.

http://marketexclusive.com/value-threshold-pharmaceuticals-inc-nasdaqthld-sell-off/33016/?icd1